ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer

This publication has 10 references indexed in Scilit:

• Ovarian cancer: Age contrasts in incidence, histology, disease stage at diagnosis, and mortality
  Cancer, 2010
• Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a hellenic co-operative oncology group study
  European Journal Of Cancer, 1996
• Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
  New England Journal of Medicine, 1996
• Impact of doxorubicin on survival in advanced ovarian cancer.
  Journal of Clinical Oncology, 1995
• The treatment of epithelial ovarian cancer
  CA: A Cancer Journal for Clinicians, 1995
• Cancer statistics, 1994
  CA: A Cancer Journal for Clinicians, 1994
• Staging Procedures, Clinical Management, and Survival Outcome for Ovarian Carcinoma
  JAMA, 1993
• Early ovarian cancer and the Icon trials
  European Journal Of Cancer, 1992
• Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.
  BMJ, 1991
• Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
  Journal of Clinical Oncology, 1989